title: In response to Furst et al, "Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin".
authors.forename: Wayne
authors.initials: W
authors.lastname: Geller
authors.forename: Mark
authors.initials: M
authors.lastname: Smith
authors.forename: Helen
authors.initials: H
authors.lastname: Winter
authors.forename: Martin
authors.initials: M
authors.lastname: Brecher
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000097:blood; D003987:Dibenzothiazepines / Q000009:adverse effects* / Q000097:blood; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000097:blood; D008133:Long QT Syndrome / Q000139:chemically induced*; D008148:Lovastatin / Q000009:adverse effects* / Q000097:blood; D000069348:Quetiapine Fumarate
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000069348:Quetiapine Fumarate; D008148:Lovastatin